[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,676,108
  • Shares Outstanding, K 29,608
  • Annual Sales, $ 234,600 K
  • Annual Income, $ -13,230 K
  • EBIT $ 41 M
  • EBITDA $ 38 M
  • 60-Month Beta 0.72
  • Price/Sales 6.91
  • Price/Cash Flow N/A
  • Price/Book 125.04

Options Overview Details

View History
  • Implied Volatility 81.44% (+1.49%)
  • Historical Volatility 83.08%
  • IV Percentile 48%
  • IV Rank 21.52%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 508
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 8,696
  • Open Int (30-Day) 5,966
  • Expected Range 56.61 to 56.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 3
  • High Estimate $0.27
  • Low Estimate $-0.84
  • Prior Year $-1.34
  • Growth Rate Est. (year over year) +83.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.71 +13.88%
on 07/21/26
70.91 -20.17%
on 07/14/26
-10.71 (-15.92%)
since 07/07/26
3-Month
49.71 +13.88%
on 07/21/26
70.91 -20.17%
on 07/14/26
-10.35 (-15.46%)
since 05/07/26
52-Week
11.40 +396.40%
on 09/16/25
72.36 -21.77%
on 05/05/26
+43.03 (+316.86%)
since 08/07/25

Most Recent Stories

More News
Anaptysbio's Pipeline Dependency: How Long Can One Candidate Carry the Entire Thesis?

Barchart Research What to Expect from ANAB Earnings ANAB Generated August 4, 2026 Current Price $55.13 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 6.30% Anaptysbio's Pipeline Dependency:...

ANAB : 56.61 (+3.36%)
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda...

ANAB : 56.61 (+3.36%)
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 56.61 (+3.36%)
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 56.61 (+3.36%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 56.61 (+3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 59.87
2nd Resistance Point 58.62
1st Resistance Point 57.62
Last Price 56.61
1st Support Level 55.37
2nd Support Level 54.12
3rd Support Level 53.12

See More

52-Week High 72.36
Last Price 56.61
Fibonacci 61.8% 49.07
Fibonacci 50% 41.88
Fibonacci 38.2% 34.69
52-Week Low 11.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.